DEVELOPMENT OF NOVEL PDE4B INHIBITORS TO TREAT ALCOHOL USE DISORDER (SBIR PHASE II)

在美国，过度饮酒每年造成近8万人死亡，并导致包括酒精中毒在内的酒精使用障碍（AUD）的发展，影响到1800万美国人。 然而，治疗的解决方案并不多。 我们最近的研究工作确定了PDE4B作为治疗AUD的有希望的靶点。 选择性PDE4B抑制剂可能成为一类新的治疗酒精中毒的药物，因为PDE4B抑制剂可以减少乙醇摄入量和偏好，而不会引起呕吐反应，这是泛PDE4抑制剂的主要副作用。

Excessive alcohol drinking is responsible for nearly 80,000 deaths per year in the U.S. and for the development of Alcohol Use Disorders (AUD) including alcoholism, which affects 18 million Americans. However, there are not many solutions for the treatment. Our recent research work indentified PDE4B as a promising target for the treatment of AUD. Selective PDE4B inhibitors could become a novel class of drugs for treatment of alcoholism given that PDE4B inhibitors may decrease ethanol intake and preference without causing emetic responses, the major side effects of pan PDE4 inhibitors.